Log In
Print
BCIQ
Print
Print this Print this
 

RenaZorb (SPI-014)

  Manage Alerts
Collapse Summary General Information
Company Spectrum Pharmaceuticals Inc.
DescriptionSecond generation lanthanum-based phosphate-binding agent
Molecular Target Not available
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationHyperphosphatemia
Indication DetailsTreat hyperphosphatemia in end stage renal disease (ESRD); Treat hyperphosphatemia in patients with chronic kidney disease (CKD)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today